BM86 Immunomodulator Vials

Other / Unclassified

This document is a "Decision to Restrict Competition" under the Simplified Acquisition Threshold, justifying a sole-source acquisition for the BM86 vaccine immunomodulator. It outlines the mission area, contracting activity, and a brief description of the supplies or services required.

This document is relevant to potential bidders as it explains why the government is restricting competition for this specific acquisition. It identifies:

• Product: BM86 vaccine immunomodulator, an experimental veterinary biological product developed by USDA ARS and manufactured by Zoetis, Inc.
• Purpose: Used for eradicating Cattle Fever Tick in infested areas of South Texas.
• Quantity: 14,000 doses required.
• Delivery: Earliest anticipated delivery date is September 1, 2026, due to a 6-month production lead time.
• Sole Source Justification: The BM86 vaccine is described as having unique qualifications, being an experimental product with no alternatives available. Zoetis, Inc. holds exclusive property rights, and USDA has prior successful experience with the vaccine. Market research indicated no other approved vaccines are available.
• Suggested Source: Zoetis, Inc.

Solicitation / RFP / RFQ

This solicitation is for the procurement of BM86 Immunomodulator 10DS 20ML vials, an injectable vaccine for the treatment of cattle fever ticks on wildlife. This is part of the USDA Cattle Fever Tick Eradication Program (CFTEP) in Texas. The government intends to make one award.

• The primary deliverable is 1,400 units of BM86 Immunomodulator 10 DS 20ML Vials.

• Delivery is required by September 1, 2026. Early deliveries are accepted.

• The F.O.B. point for all deliverables is destination.

• Award type is anticipated to be a firm-fixed price purchase order.

• The period for acceptance of offers is 90 calendar days from the date specified for receipt of offers.

• The proposed contractor, Zoetis Inc., has exclusive property rights to this product, indicating a noncompetitive action.

• Quotes will be evaluated based on Technical Approach, Price, and Past Performance.

• Award will be made to the offeror representing the best value to the Government, not necessarily the lowest-priced offeror. Tradeoffs will not be conducted.

• Technical Approach: USDA requires 1,400 BM86 Immunomodulator 10 DS 20ML Vials.

• Price: Offerors must include quantity price discounts and prompt payment discounts. The quotation will be evaluated for fairness and reasonableness.

• Past Performance: Will be evaluated as Acceptable, Neutral, or Unacceptable based on demonstrated ability to meet contract requirements, timeliness, cost control, business relations, and adherence to terms.

• The highest technically rated offeror will be selected, provided their price is fair and reasonable and past performance is acceptable or neutral.

• The acquisition is currently marked as UNRESTRICTED.

• Questions are due by March 26, 2026, at 3:00 PM Eastern Time and should be submitted via email to Kathy.Melby@usda.gov.

• The solicitation incorporates numerous FAR clauses by reference, including those related to commercial products and services, contractor responsibilities, and various certifications.